DURECT (DRRX)
(Delayed Data from NSDQ)
$1.67 USD
-0.01 (-0.30%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 101 - 120 ( 143 total )
Company: DURECT Corporation
Industry: Medical - Drugs
A Treat From DUR-928 on Halloween; Reiterate Buy and Raising Price Target to $4
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
A Treat From DUR-928 on Halloween; Reiterate Buy and Raising Price Target to $4
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Receives Complete Response Letter; Reiterate Buy, Adjusting Price Target to $3.50
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
REMOXY? Receives Complete Response Letter; Reiterate Buy, Adjusting Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
2Q16 Results
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
2Q16 Results; REMOXY? Approval Near Term; DUR-928 Data in 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
FDA Panel for REMOXY Deemed Unnecessary; Near-term Approval Likely; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
FDA Panel for REMOXY Deemed Unnecessary; Near-term Approval Likely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
2016 1Q Financial Results; Multiple Trials Reporting Later This Year; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
2016 1Q Financial Results; Multiple Trials Reporting Later This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
We are Initiating Coverage at Buy Rating and $4.00 Price Target
Provider: Rodman & Renshaw, Co.
Company: DURECT Corporation
Industry: Medical - Drugs
We are initiating coverage of DURECT Corporation with a Buy rating and a 12-month price target of $4.00 per share
Provider: H.C. Wainwright & Co., Inc.
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J